Join the Semaglutide group to help and get support from people like you.
Semaglutide News (Page 7)
Wegovy, Ozempic May Help Curb Alcohol Dependence
TUESDAY, June 4, 2024 – Could the blockbuster GLP-1 meds like Wegovy and Ozempic have a role to play in helping people cut down on problem drinking? A new study suggests so. Researchers at Case...
GLP-1 Weight Loss Meds Might Keep Your Pancreas Healthy
MONDAY, June 3, 2024 – Ozempic and Wegovy might help lower the risk of pancreatitis in patients with obesity and type 2 diabetes, a new study says. Up to now, doctors have been cautious about...
Could New Weight-Loss Drugs Be Changing Women's Taste for Sweets?
MONDAY, June 3, 2024 – Ozempic and Wegovy appear to improve people’s sensitivity to tastes, potentially lowering their desire for sweets, a new study suggests. The active ingredient in the w...
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 – For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from cardiovascular causes,...
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 – Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease, according to a study...
Costs, Side Effects Drive Folks to Quit New Weight-Loss Meds
THURSDAY, May 23, 2024 – Three months after starting one of the new GLP-1 weight-loss drugs, more than a quarter of patients have already quit the medications, and by a year from first use more than...
Use of GLP-1 Meds Have Risen 7-Fold Among Young Americans
WEDNESDAY, May 22, 2024 – The number of American teens and young adults who've been prescribed one of the new GLP-1 weight-loss drugs soared nearly seven-fold between 2020 and 2023, a new report...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 – For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research letter published...
'Hungry Gut' Gene Test Shows Who'll Benefit Most From Wegovy
TUESDAY, May 21, 2024 – You've watched others shed pounds in a matter of weeks after taking one of the new blockbuster weight-loss drugs, so you decide to try one of the medications yourself, only...
Semaglutide Has Lasting Benefit for Weight Loss
TUESDAY, May 21, 2024 – Semaglutide has a long-term beneficial impact on weight, as well as cardiovascular benefits, regardless of weight loss, according to two studies presented at the annual...
Semaglutide Reduces Need for Diuretics in Heart Failure
THURSDAY, May 16, 2024 – Semaglutide reduces the need for loop diuretics and has positive effects on symptoms, physical limitations, and body weight in patients with heart failure with preserved...
Four in 10 Adults With Diabetes Report Taking a GLP-1 Receptor Agonist
TUESDAY, May 14, 2024 – One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent say they are currently using one, according to...
GLP-1 Receptor Agonist Use Increases Likelihood of Antidepressant Prescription
WEDNESDAY, May 15, 2024 – Individuals taking glucagon-like peptide (GLP)-1 receptor agonists have a greater risk for subsequently being dispensed antidepressants, according to a study published...
More Studies Support Wegovy's Long-Term Weight-Loss Benefits
TUESDAY, May 14, 2024 – Semaglutide – the active ingredient in the blockbuster weight-loss drugs Ozempic and Wegovy – can produce long-term weight and heart health benefits, a pair of new studies...
Wegovy Approved in the US for Cardiovascular Risk Reduction in People with Overweight or Obesity and Established Cardiovascular Disease
Bagsværd, Denmark, 8 March 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy based on a supplemental New Drug Application (s...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Cardiovascular Risk Reduction, Chronic Kidney Disease, Diabetes, Type 2